Targeted anti-mitotic therapies: Can we improve on tubulin agents?

Nature Reviews Cancer

Volumn 7, Issue 2, 2007, Pages 107-117

  Jackson, Jeffrey R ^a   Patrick, Denis R ^a   Dar, Mohammed M ^a   Huang, Pearl S ^b  

^a GLAXOSMITHKLINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; ARRY 649; AURORA A KINASE; AURORA B KINASE; AURORA KINASE INHIBITOR; AZD 1152; BI 2536; CENTROMERE PROTEIN E; CK 0106023; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; CYTARABINE; DOCETAXEL; DOXORUBICIN; GSK 923295; IDARUBICIN; ISPINESIB; KINESIN; LIVER ENZYME; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MK 0731; MLN 8054; NAVELBINE; ON 01910; PACLITAXEL; PHA 680632; POLO LIKE KINASE; SB 743921; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; BILE DUCT CARCINOMA; BILIRUBIN BLOOD LEVEL; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER; CANCER THERAPY; CARDIOTOXICITY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CHEMOTHERAPY INDUCED EMESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG DOSE ESCALATION; DRUG POTENCY; DRUG TARGETING; ENZYME BLOOD LEVEL; FATIGUE; FEBRILE NEUTROPENIA; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; HODGKIN DISEASE; HUMAN; HYPERBILIRUBINEMIA; INFECTION; LEUKOPENIA; LIVER CELL CARCINOMA; LUNG SMALL CELL CANCER; MELANOMA; METAPHASE; MITOSIS; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RECTUM CARCINOMA; REVIEW; SIDE EFFECT; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA; UTERINE CERVIX CANCER;

ANIMALS; HUMANS; MITOSIS; TUBULIN;

EID: 33846523617     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc2049     Document Type: Review

References (80)

1. Wood, K. W. et al. Past and future of the mitotic spindle as an oncology target. Curr. Opin. Pharmacol. 1, 370-377 (2001).
2. Nigg, E. A., Blangy, A. & Lane, H. A. Dynamic changes in nuclear architecture during mitosis: on the role of protein phosphorylation in spindle assembly and chromosome segregation. Exp. Cell Res. 229, 174-180 (1996).
3. Keen, N. & Taylor, S. Aurora-kinase inhibitors as anticancer agents. Nature Rev. Cancer 4, 927-936 (2004).
4. Strebhardt, K., Ullrich, A., Authors, F. N. & Ullrich, A. Targeting polo-like kinase 1 for cancer therapy. Nature Rev. Cancer 6, 321-330 (2006).
5. Blangy, A. et al. Phosphorylation by p34cdc2 regulates spindle association of human Eg5,a kinesin-related motor essential for bipolar spindle formation in vivo. Cell 83, 1159-1169 (1995).
6. Schaar, B. T. et al. CENP-E function at kinetochores is essential for chromosome alignment. J. Cell Biol. 139, 1373-1382 (1997).
7. Wood, K. W. et al. CENP-E is a plus end-directed kinetochore motor required for metaphase chromosome alignment. Cell 91, 357-366 (1997).
8. Abrieu, A. et al. CENP-E as an essential component of the mitotic checkpoint in vitro. Cell 102, 817-826 (2000). This thought-provoking study shows the crucial role of CENPE in mitotic-spindle checkpoint regulation in addition to its previously known role in chromosome alignment.
9. Tao, W. et al. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell 8, 49-59 (2005). This study shows that mitotic arrest alone can be insufficient to cause tumour cell death, and that subsequent events ultimately define cell fate.
10. Jordan, M. A. et al. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res. 56, 816-825 (1996).
11. Marcus, A. I. et al. Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and-sensitive cancer cells. J. Biol. Chem. 280, 11569-11577 (2005).
12. Castedo, M. et al. Cell death by mitotic catastrophe: a molecular definition. Oncogene 23, 2825-2837 (2004).
13. Michel, L. et al. Complete loss of the tumor suppressor MAD2 causes premature cyclin B degradation and mitotic failure in human somatic cells. Proc. Natl Acad. Sci. USA 101, 4459-4464 (2004).
14. Kops, G. J. P. L., Foltz, D. R. & Cleveland, D. W. Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc. Natl Acad. Sci. USA 101, 8699-8704 (2004).
15. Michel, L., Benezra, R. & Diaz-Rodriguez, E. A double edged sword: MAD2 dependent mitotic checkpoint defects in tumorigenesis and tumor cell death. Cell Cycle 3, 990-992 (2006).
16. Ditchfield, C. et al. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J. Cell Biol. 161, 267-280 (2003).
17. Kashina, A. S. et al. The bimC family of kinesins: essential bipolar mitotic motors driving centrosome separation. Biochimica Biophysica Acta 1357, 257-271 (1997).
18. Hegde, P. S. et al. Differential gene expression analysis of kinesin spindle protein in human solid tumors. Proc. Am. Soc. Clin. Oncol. 22, 535 (2003).
19. Mayer, T. U. et al. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 286, 971-974 (1999). The first study to show that selective inhibitors of KSP could be identified and shown to have excellent anti-mitotic activity
20. Sakowicz, R. et al. Antitumor activity of a kinesin inhibitor. Cancer Res. 64, 3276-3280 (2004).
21. Brier, S. et al. Identification of the protein binding region of S-trityl-L-cysteine, a new potent inhibitor of the mitotic kinesin Eg5. Biochemistry 43, 13072-13082 (2004).
22. Debonis, S. et al. In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities. Mol. Cancer Ther. 3, 1079-1090 (2004).
23. Gartner, M. et al. Development and biological evaluation of potent and specific inhibitors of mitotic Kinesin Eg5. Chembiochem. 6, 1173-1177 (2005).
24. Sunder-Plassmann, N. et al. Synthesis and biological evaluation of new tetrahydro-beta-carbolines as inhibitors of the mitotic kinesin Eg5. Bioorg. Med. Chem. 13, 6094-6111 (2005).
25. Cox, C. D. et al. Kinesin spindle protein (KSP) inhibitors. Part 1: the discovery of 3, 5-diaryl-4, 5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP. Bioorg. Med. Chem. Lett. 15, 2041-2045 (2005).
26. Yan, Y. et al. Inhibition of a mitotic motor protein: where, how, and conformational consequences. J. Mol. Biol. 335, 547-554 (2004).
27. Johnson, R. K. et al. SB-715992, a potent and selective inhbitor of the mitotic kinesin KSP, demonstrates broad-spectrum activity in advanced murine tumors and human tumor xenografts. Proc. Am. Assoc. Can. Res. 43, 269 (2002).
28. Gonzales, P. et al. Breadth of anti-tumor activity of CK0238273 (SB-715992), a novel inhibitor of the mitotic kinesin KSP. Proc. Am. Assoc. Can. Res. 43, 269 (2002).
29. Lobell, R. B. et al. In vivo characterization of an inhibitor of the mitotic kinesin, KSP: pharacodynamics, efficacy, and tolerability in xenograft tumor models. Proc. AACR-NCI-EORTC Mol. Tar. Can. Ther. Mtg Abst. B189 (2005).
30. Garcia-Saez, I. et al. Crystal structure of the motor domain of the human kinetochore protein CENP-E. J. Mol. Biol. 340, 1107-1116 (2004).
31. Liu, D. et al. Interaction of Skp1 with CENP-E at the midbody is essential for cytokinesis. Biochem. Biophys. Res. Comm. 345, 394-402 (2006).
32. Yao, X. et al. The microtubule-dependent motor centromere-associated protein E (CENP-E) is an integral component of kinetochore corona fibers that link centromeres to spindle microtubules. J. Cell Biol. 139, 435-447 (1997).
33. Chan, G. K. et al. Human BUBR1 is a mitotic checkpoint kinase that monitors CENP-E functions at kinetochores and binds the cyclosome/APC. J. Cell Biol. 146, 941-954 (1999).
34. Mao, Y. et al. Activating and silencing the mitotic checkpoint through CENP-E-dependent activation/inactivation of BubR1. Cell 114, 87-98 (2003).
35. McEwen, B. F. et al. CENP-E is essential for reliable bioriented spindle attachment, but chromosome alignment can be achieved via redundant mechanisms in mammalian cells. Mol. Biol. Cell 12, 2776-2789 (2001).
36. Yao, X. et al. CENP-E forms a link between attachment of spindle microtubules to kinetochores and the mitotic checkpoint. Nature Cell Biol. 2, 484-491 (2000).
37. Kapoor, T. M. et al. Chromosomes can congress to the metaphase plate before biorientation. Science 311, 388-391 (2006).
38. Putkey, F. R. et al. Unstable kinetochore-microtubule capture and chromosomal instability following deletion of CENP-E. Dev. Cell 3, 351-365 (2002).
39. Andrews, P. D., Knatko, E., Moore, W. J. & Swedlow, J. R. Mitotic mechanics: the auroras come into view. Curr. Opin. Cell Biol. 15, 672-683 (2003).
40. Marumoto, T., Zhang, D. & Saya, H. Aurora-A- a guardian of poles. Nature Rev. Cancer 5, 42-50 (2005).
41. Matthews, N., Visintin, C., Hartzoulakis, B., Jarvis, A. & Selwood, D. L. Aurora A and B kinases as targets for cancer: will they be selective for tumors? Expert Rev. Anticancer Ther. 6, 109-120 (2006).
42. Ecsedy, J. A. et al. Effect of aurora A inhibition in cultured human tumor cells using the selective small molecule inhibitor MLN8054. AACR Meeting Abstracts 2006 488 (2006).
43. Giet, R. et al. Drosophila Aurora A kinase is required to localize D-TACC to centrosomes and to regulate astral microtubules. J. Cell Biol. 156, 437-451 (2002).
44. Hannak, E., Kirkham, M., Hyman, A. A. & Oegema, K. Aurora-A kinase is required for centrosome maturation in Caenorhabditis elegans. J. Cell Biol. 155, 1109-1116 (2001).
45. Adams, R. R., Maiato, H., Earnshaw, W. C. & Carmena, M. Essential roles of Drosophila inner centromere protein (INCENP) and aurora B in histone H3 phosphorylation, metaphase chromosome alignment, kinetochore disjunction, and chromosome segregation. J. Cell Biol. 153, 865-880 (2001).
46. Hauf, S. et al. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J. Cell Biol. 161, 281-294 (2003).
47. Gizatullin, F. et al. The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res. 66, 7668-7677 (2006).
48. Yang, H. et al. Mitotic requirement for aurora A kinase is bypassed in the absence of aurora B kinase. FEBS Lett. 579, 3385-3391 (2005).
49. Hoover, R. R. & Harding, M. W. Synergistic activity of the aurora kinase inhibitor MK-0457 (VX-680) with idarubicin, Ara-C, and inhibitors of BCR-ABL. ASH Annual Meeting Abstracts 108, 1384 (2006).
50. Barr, F. A., Sillje, H. H. W. & Nigg, E. A. Polo-like kinases and the orchestration of cell division. Nature Rev. Mol. Cell Biol. 5, 429-440 (2004).
51. Takai, N., Hamanaka, R., Yoshimatsu, J. & Miyakawa, I. Polo-like kinases (Plks) and cancer. Oncogene 24, 287-291 (2005).
52. Eckerdt, F., Yuan, J. & Strebhardt, K. Polo-like kinases and oncogenesis. Oncogene 24, 267-276 (2005).
53. Sumara, I. et al. Roles of polo-like kinase 1 in the assembly of functional mitotic spindles. Curr. Biol. 14, 1712-1722 (2004).
54. Liu, X. Q. & Erikson, R. L. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc. Natl Acad. Sci. USA 100, 5789-5794 (2003).
55. Chu, Q. S. et al. Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV Q 21 days. J. Clin. Oncol. 22, 2078 (2004).
56. Chu, Q. S. et al. A phase I study to determine the safety and pharmacokinetics of IV administered SB-715992, a novel kinesin spindle protein (KSP) inhibitor, in patients (pts) with solid tumors. Proc. Am. Soc. Clin. Oncol. 22, 525 (2003).
57. Burris, H. A. et al. Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV days 1, 8, 15 q 28 days. J. Clin. Oncol. 22, 2004 (2004).
58. Miller, K. et al. Phase II, open label study of SB-715992 (ispinesib) in subjects with advanced or metastatic breast cancer. San Antonio Breast Cancer Symp. abst. 1089 (2005).
59. Jackson, J. R. et al. A second generation KSP inhibitor, SB-743921, is a highly potent and active therapeutic in preclinical models of cancer. AACR Meeting Abstracts 2006, B11 (2006).
60. Holen, K. D. et al. Phase I study to determine tolerability and pharmacokinetics (PK) of SB-743921, a novel kinesin spindle protein (KSP) inhibitor. J. Clin. Oncol. 24, 2000 (2006).
61. Holen, K. D. et al. Phase I study to determine tolerability and pharmacokinetics (PK) of SB-743921, a novel kinesin spindle protein (KSP) inhibitor. J. Clin. Oncol. 23, 2010 (2005).
62. Stein, M. N. et al. Phase I clinical and pharmacokinetic (PK) trial of the kinesin spindle protein (KSP) inhibitor MK-0731 in cancer patients. J. Clin. Oncol. 24, 2001 (2006).
63. Rubin, E. H. et al. A phase I clinical and pharmacokinetic (PK) trial of the aurora kinase (AK) inhibitor MK-0457 in cancer patients. J. Clin. Oncol. 24, 3009 (2006).
64. Schellens, J. H. et al. Phase I and pharmacological study of the novel aurora kinase inhibitor AZD1152. J. Clin. Oncol. 24, 3008 (2006).
65. Hofheinz, R. et al. A phase I repeated dose escalation study of the Polo-like kinase 1 inhibitor BI 2536 in patients with advanced solid tumours. J. Clin. Oncol. 24, 2038 (2006).
66. Munzert, G. et al. A phase I study of two administration schedules of the Polo-like kinase 1 inhibitor BI 2536 in patients with advanced solid tumors. J. Clin. Oncol. 24, 3069 (2006).
67. Ohnuma, T. et al. Phase I study of ON 01910. Na by 3-day continuous infusion (CI) in patients (pts) with advanced cancer. J. Clin. Oncol. 24, 13137 (2006).
68. Donehower, R. C. et al. Phase I study of ON-01910. Na, a novel cell cycle inhibitor in adult patients with solid tumors. J. Clin. Oncol. 24, 13026 (2006).
69. Steegmaier, M. et al. BI 2536, a potent and highly selective inhibitor of Polo-like kinase 1 (Plk1), induces mitotic arrest and apoptosis in a broad spectrum of tumor cell lines. Clin. Cancer Res. 11, 9147 (2005).
70. Cogswell, J. P., Brown, C. E., Bisi, J. E. & Neill, S. D. Dominant-negative polo-like kinase 1 induces mitotic catastrophe independent of cdc25C function. Cell Growth Differ. 11, 615-623 (2000).
71. Soncini, C. et al. PHA-680632, a novel aurora kinase inhibitor with potent antitumoral activity. Clin. Cancer Res. 12, 4080-4089 (2006).
72. Chang, J. C. et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362, 362-369 (2003). This landmark study showed that gene-expression profiles from patient tumour samples can predict whether the disease will respond to taxane therapy.
73. Gianni, L. et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J. Clin. Oncol. 23, 7265-7277 (2005).
74. Komatsu, M. et al. Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers. Mol. Cancer Ther. 5, 767-775 (2006).
75. Magne, N., Largillier, R., Marcy, P. Y., Magne, J. & Namer, M. Cardiac toxicity assessment in locally advanced breast cancer treated neoadjuvantly with doxorubicin/paclitaxel regimen. Supp. Care Cancer 13, 819-825 (2005).
76. Holmes, F. A. et al. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase i study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J. Clin. Oncol. 14, 2713-2721 (1996).
77. Mondesire, W. H. et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin. Cancer Res. 10, 7031-7042 (2004).
78. Kenny, L. M. et al. Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine- positron emission tomography imaging: evaluation of analytical methods. Cancer Res. 65, 10104-10112 (2005).
79. Kenny, L. M. et al. Early assessment of response to treatment in breast cancer by [18F]fluorothymidine-positron emission tomography. J. Clin. Oncol. (Meeting Abstracts) 23, 2084 (2005).
80. Cleveland, D. W., Mao, Y. & Sullivan, K. F. Centromeres and kinetochores: from epigenetics to mitotic checkpoint signaling. Cell 112, 407-421 (2003).